Armata Posts 59 Percent Q2 Revenue Jump

Armata Pharmaceuticals (NYSEMKT:ARMP), a clinical-stage biotech developing bacteriophage therapies for drug-resistant bacterial infections, released its second-quarter results on August 12, 2025. The company posted GAAP revenue of $2.2 million, beating analyst GAAP revenue estimates of $1.38 million, mostly due to grant and award funding led by the U.S. Department of Defense.The period was defined by major clinical progress—positive Phase 1b/2a results for its AP-SA02 candidate—yet also by continued financial strain as Armata seeks new funding for future trials. Source: Analyst estimates for the quarter provided by FactSet. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool